Site A has an above-threshold protocol deviation rate (>4%) or a high volume of overdue queries (n=75+), the next onsite visit would emphasize those metrics.

Thus, central review enables data-driven, targeted monitoring—a key tenet of RBM implementation.

Case Study: Optimizing CRA Visit Based on Central Findings

In a global vaccine trial, central monitors observed consistent discrepancies in visit dates at Site 008. The CRA was notified to prioritize verifying source documents related to visit scheduling and subject dosing. During the onsite visit, the CRA discovered that the site coordinator had misunderstood the visit window algorithm in the EDC. This led to a corrective training and update in site SOP.

This real-time feedback loop—between central review and CRA actions—enhanced protocol adherence and prevented a larger compliance issue. You can learn more about these SOPs at PharmaSOP: Hybrid Monitoring SOP Templates.

Enhancing CRA Efficiency Through Centralized Insights

Onsite monitors often face time constraints and administrative overload. Central review alleviates this by pre-screening data and generating visit agendas. Examples include:

• Pre-visit reports highlighting open issues
• Summary of delayed AE/SAE entries per subject
• Subject dropout reasons by site
• Query aging reports (e.g., queries open >15 days)

These insights allow CRAs to arrive at the site with a prioritized checklist, saving hours of document navigation. It also enables focused discussions with site staff and better oversight documentation in the Trial Master File (TMF).

Data-Driven Triggers for Remote and Onsite Escalation

Central review is critical in initiating timely escalations and prompting onsite action. Some examples include:

• SAE Reporting Delays: If the time from event onset to EDC entry exceeds 5 days
• Data Fabrication Suspicion: Repeated identical vital signs or lab values
• High Subject Withdrawal Rate: >20% dropouts at a single site
• Incomplete ICF Uploads: Missing signed consent in EDC or eTMF

Each of these triggers may warrant immediate site contact, targeted CRA visit, or Quality Assurance (QA) audit. The documentation of signal review and escalation steps must be captured in a centralized RBM log or risk signal tracker.

Tools Enabling Central and Onsite Integration

Modern clinical platforms allow seamless collaboration between centralized reviewers and CRAs. Tools include:

• EDC with built-in RBM dashboards (e.g., Medidata Rave, Oracle Clinical One)
• Site dashboards in CTMS that track protocol deviations, enrollment, and SDV progress
• JIRA or ticketing tools to assign findings to CRAs for resolution
• Audit Trail and eTMF integration to archive actions and confirmations

Visit the resources section at PharmaValidation: Centralized Monitoring Compliance Tools for validated templates and tracker examples.

Regulatory Support for Hybrid Monitoring Models

Both FDA and EMA support hybrid monitoring approaches under RBM, encouraging central oversight complemented by strategic onsite visits. ICH E6(R2) explicitly recommends a mix of centralized and on-site activities based on risk assessments. Inspectors will often look for:

• Documented rationale for site selection and visit frequency
• Linkage between central findings and site action plans
• Evidence of communication between central monitors and CRAs
• Archived risk signals and resulting follow-up logs

Proper documentation ensures inspection readiness and alignment with global GCP expectations.

Challenges in Hybrid Monitoring Implementation

Despite its benefits, integrating central review with onsite monitoring poses challenges:

• Delayed Data Entry: Central review is only as good as the timeliness of EDC updates
• Communication Gaps: Misalignment between central teams and field CRAs
• Lack of SOPs: Hybrid processes often lack formal documentation
• Tool Fragmentation: Using multiple, disconnected systems hinders visibility

To mitigate this, sponsors should establish centralized escalation SOPs, communication protocols, and system integration plans.

Conclusion

Centralized review does not replace onsite monitoring—it strengthens it. By providing real-time, data-driven insights, it allows CRAs to target risk areas, optimize their visits, and contribute to better compliance, safety, and quality. The hybrid model is now a regulatory-endorsed standard, and sponsors must invest in the right tools, training, and SOPs to operationalize this synergy effectively.

Further Reading

• FDA Guidance on Risk-Based Monitoring
• ICH E6(R2) Guidelines